本帖最后由 老马 于 2013-3-13 13:43 编辑 5 t5 P6 k5 b- a" [3 o
) C/ Q3 w# b, U+ d2 T7 T健择（吉西他滨）+顺铂+阿瓦斯汀3 w- X/ k' t+ J; n# K8 O
Gemzar +Cisplatin + Avastin6 q) {, a* X! y) M9 P4 f5 |
http://annonc.oxfordjournals.org/content/21/9/1804.full M6 w8 @# Q: p3 U$ P: e: G' t
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& O7 b$ Q) X( zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 1 C* T, l! y' ~& W- I6 h
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 l' L' U7 ?5 W" R
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 242)
+ O7 b$ { x9 ]2 ^ m' d* \% D% g华为网盘附件：
: R! [8 K" H" S5 j$ W【华为网盘】ava.JPG! D5 o& P: _6 p3 a$ L/ G% L
|
显身卡
